UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2011	Oct. 31, 2010
Operating revenue:
Personalized oncology solutions	$ 590	$ 288	$ 1,188	$ 1,397
Translational oncology solutions	1,151	645	2,184	1,136
Total operating revenue	1,741	933	3,372	2,533
Costs and operating expenses:
Cost of personalized oncology solutions	461	164	945	489
Cost of translational oncology solutions	620	395	1,104	711
Research and development	1,008	673	1,616	1,502
Sales and marketing	651	80	1,262	116
General and administrative	1,470	636	3,130	1,325
Total costs and operating expenses	4,210	1,948	8,057	4,143
Loss from operations	(2,469)	(1,015)	(4,685)	(1,610)
Other income:
Grant income	0	961	0	965
Change in fair value of warrant liability	110	0	288	0
Other income	10	0	10
Total other income	120	961	298	965
Loss before provision for income taxes	(2,349)	(54)	(4,387)	(645)
Provision for income taxes	0	0	0	0
Net loss	(2,349)	(54)	(4,387)	(645)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.05)	$ 0	$ (0.09)	$ (0.02)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	$ 46,790,000	$ 35,677,000	$ 46,606,000	$ 35,707,000